Showing results (571-580 of 895) with videos related to
Sort By:
Pageof 90
Drugs in R&D|July 5, 2005
Rufinamide: CGP 33101, E 2080, RUF 331, XilepDrugs in R&D|May 5, 2005
Cilansetron: KC 9946Drugs in R&D|May 5, 2005
Ramelteon: TAK 375Drugs in R&D|June 21, 2006
Nitronaproxen: AZD 3582, HCT 3012, Naproxen Nitroxybutylester, NO-NaproxenDrugs in R&D|March 8, 2002
Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre studyMichael Soyka, Ulrich Preuss, Christian SchuetzDrugs in R&D|June 20, 2025
Systematic Review and Meta-analysis of the Clinical Efficacy of Octreotide in Combination with Ulinastatin in the Treatment of Acute PancreatitisLong-Xun Zhu, Yong Chen, Xiang-Fan Chen, et al.Drugs in R&D|June 26, 2025
In-Vitro Comparison of Physical Characteristics, Enzyme Content, and Release Kinetics of Pancreatic Enzyme Preparations Available in Europe and CanadaSven Hartmann, Jonas Rosendahl, Amy Todd, et al.Drugs in R&D|August 9, 2025
Assessment of Pharmacokinetics and Safety with Bioequivalence of the Nitroglycerin Sublingual Tablets of Two Formulations in Chinese Healthy Subjects: A Bioequivalence StudyQinjiao Fu, Chunqi Huang, Yuan Yuan, et al.Drugs in R&D|July 31, 2025
Effect of Severe Renal Impairment on Dordaviprone (ONC201) PharmacokineticsShamia L Faison, Joelle Batonga, Thangam Arumugham, et al.Drugs in R&D|September 18, 2013
Investigation of the hemostatic effect of a transdermal patch containing 0.55 mg ethinyl estradiol and 2.1 mg gestodene compared with a monophasic oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel: an open-label, randomized, crossover studyWolfgang Junge, Doris Heger-Mahn, Dietmar Trummer, et al.Pageof 90